【摘要】 1978～1989年在食管癌高发现场用复合核黄素对食管上皮重度增生患者进行阻断治疗,约2年吞(拉)网细胞学随诊一次,共6次。本文报告137例效果评价分析。第6年时与对照组比较,两组好转率分别为47.2%(42/89)及20%(7/35),进展率为19.1%(17/89)和42.9%(15/35),癌变率为1.1%(1/89)及14.3%(5/35),两组间差别均有显著性(P<0.025)。治疗组第12年好转率为46.6%(34/73),癌变率为5.5%(4/73)。12年中累计发现癌患者8例,占5.8%。远低于文献回顾调查1～12年的自然癌变率(14.9%,79/530)。更多还原

【Abstract】 Since the spring of 1978,137 individuals suffering from esophageal dysplasia detected by balloon cytology in the Hebi suburbs of Henan province had been treated with compound riboflavin. Periodic follow-up examination with cytology to check the treating effect has been taken every 1～2 or more years. Up to 1989, six examinations had been done. A comparison between the treated group and the control group with the results on the 6th year was done. It was revealed that the regression rate in the treatment group was 47.2%(42/89), the progression rate 19.1%(17/89) and the canceration rate 1.1%(1/89), while in the control group the regression rate was 20%(7/35), the progressive rate 42.9%(15/35) and the canceration rate 14.3%(5/35). The statistic differences were significant(P<0.05). In the 137 cases followed up for 12 years(1989), the regression rate was 46.6%(34/73) and the canceration rate 5.5%(4/73).Eight cancers were found out of the 137 dysplasia in 12 years. The canceration rate was 5.8%. In comparison with the data obtained by retrospective survey in 530 cases of esophageal dysplasia without receiving any major treatment in Linxian for 1～12 years, 79 cancers were found. The canceration rate was 14.9%(79/530).更多还原